Evidence map›Paper›PMID 37654496›Full record

ArticleFrontiers in immunology2023

The PID Odyssey 2030: outlooks, unmet needs, hurdles, and opportunities - proceedings from the IPOPI global multi-stakeholders' summit (June 2022).

Susan Tadros, Johan Prévot, Isabelle Meyts, Silvia Sánchez-Ramón, Nahla H Erwa, Alain Fischer, Guillaume Lefevre, Matthew Hotchko, Peter M Jaworski, Helen Leavis and 7 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Susan TadrosDepartment of Immunology, Royal Free London NHS Foundation Trust, London, United Kingdom.
Johan PrévotIPOPI, Brussels, Belgium.
Isabelle MeytsDepartment of Pediatrics, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Silvia Sánchez-RamónDepartment of Immunology, Health Research Institute of the Hospital Clínico San Carlos (IdISSC), IML and IdISSC, Madrid, Spain.
Nahla H ErwaFaculty of Medicine, University of Khartoum, Khartoum, Sudan.
Alain FischerPediatric Hematology-Immunology and Rheumatology Unit, Necker-Enfants malades University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Guillaume LefevreUniv. Lille, Inserm, CHU Lille, U1286 - INFINITE Institut de recherche translationnelle sur l'inflammation, Lille, France.
Matthew HotchkoMarketing Research Bureau, Inc., Yakima, WA, United States.
Peter M JaworskiStrategy, Ethics, Economics, and Public Policy, McDonough School of Business, Georgetown University, Washington, DC, United States.
Helen LeavisDepartment of Rheumatology & Clinical Immunology, University Medical Center (UMC), Utrecht University, Utrecht, Netherlands.
Cornelis BoersmaHealth-Ecore B.V., Zeist, Netherlands.
Jose DrabwellIPOPI, Brussels, Belgium.
Martin van HagenDepartment of Internal Medicine, Division of Allergy & Clinical Immunology, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands.
Samya Van CoillieIPOPI, Brussels, Belgium.
Martine PergentIPOPI, Brussels, Belgium.
Siobhan O BurnsDepartment of Immunology, Royal Free London NHS Foundation Trust, London, United Kingdom.
Nizar MahlaouiIPOPI, Brussels, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IPOPI held its first Global Multi-Stakeholders' Summit on 23-24 June 2022 in Cascais, Portugal. This IPOPI initiative was designed to set the stage for a stimulating forward-thinking meeting and brainstorming discussion among stakeholders on the future priorities of the PID community. All participants were actively engaged in the entire Summit, bringing provocative questions to ensure a high level of discussion and engagement, and partnered in identifying the outlooks, unmet needs, hurdles and opportunities of PIDs for 2030. The topics that were covered include diagnosis (e.g., newborn screening [NBS], genomic sequencing- including ethical aspects on the application of genomics on NBS, the role of more accurate and timely diagnostics in impacting personalized management), treatment (e.g., the therapeutic evolution of immunoglobulins in a global environment, new therapies such as targeted therapies, new approaches in curative therapies), the interactions of Primary ID with Secondary ID, Autoinflammatory Diseases and other diseases as the field experiences an incessant evolution, and also the avenues for research in the field of humanities and human sciences such as Patient-Reported Outcome Measures (PROMs), Patient-Reported Experience Measures (PREMs), and Health-Related Quality Of Life (HRQoL). During this meeting, all participants contributed to the drafting of recommendations based on our common understanding of the future opportunities, challenges, and scenarios. As a collection of materials, perspectives and summaries, they are succinct and impactful and may help determine some of the next key steps for the PID community.

Indexed as

Pelvic Inflammatory DiseasePhenindioneChromosome MappingFemaleGenomicsHumanitiesHumansInfant, NewbornNeonatal ScreeningQuality of LifePhenindionegene therapyhematopoietic stem cell transplantationimmunoglobulin replacement therapy/plasma derived medicinal productsnewborn screeningnext generation sequencingprimary immunodeficiencies/inborn errors of immunityquality of lifetargeted therapies/personalized medicine

Identifiers

PMID37654496
PMCPMC10465327

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.